Revilla MP, Linares VJA, Lukic A, Artero BP, Bascompte CR, Matajira CT, Portero PP, Ruiz AJR

Language: Spanish
References: 17
Page: 151-156
PDF size: 165.19 Kb.

ABSTRACT

Introduction and objectives: The effectiveness of the administration of isotonic saline solution and N-cetylcysteine shows different results in the prevention of iodine contrast nephropathy. Our objective was to assess the potential effectiveness of this combined strategy in patients at high risk for contrast-induced nephropathy, who were admitted in our center for percutaneous coronary intervention due to non-ST-segment elevation acute coronary syndrome.
Method: This strategy was applied in the patients mentioned, with at least one risk factor for developing contrast-induced nephropathy: over 80 years, diabetes mellitus, baseline creatinine greater than 1.5 mg/dl or high volume of contrast (greater than 400 ml). The protocol was applied for 12 months (patients that received the prevention protocol) and compared with similar patients in the previous 12 months who received no prophylaxis.
Results: A total of 30 patients (24%) developed contrast-induced nephropathy. The percentage was significantly higher in the group that did not receive prophylaxis: 35.9 % vs. 11.5 % (p = 0.003).
Conclusions: The combination of N-acetylcysteine orally and parenteral hydration in high-risk patients with acute coronary syndrome without ST elevation could be beneficial to avoid the appearance of contrast-induced nephropathy.

REFERENCES

1. Vercellino M, Bezante GP, Balbi M. Contrast me-dium induced nephropathy: new insights into pre-vention and risk management. Cardiovasc Hematol Agents Med Chem. 2009;7(2):166-80.

2. Chong E, Poh KK, Shen L, Chai P, Tan HC. Diabe-tic patients with normal baseline renal function are at increased risk of developing contrast-induced nephropathy post-percutaneous coronary intervene-tion. Singapore Med J. 2009;50 (3):250-4.

3. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iako-vou I, Fahy M, et al. A simple risk score prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004; 44(7):1393-9.

4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-64.

5. Jian-hua LI, Neng-shu HE. Prevention of iodinated contrast-induced nephropathy. Chinese Medical Journal. 2011;124(23):4079-82.

6. Nallamoth BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci, et al. Is acetylcysteine effec-tive in preventing contrast-related nephropathy? A meta-analysis. Am J Med. 2004;117(12):938-47.

7. Gonzales DA, Norsworthy KL, Kern SJ, Banks S, Slevng PC, Star RA, et al. A meta-analysis of N-acetylcysteinein contras-induced nephrotoxicity: un-supervised clustering to resolve heterogeneity. BMC Med. 2007;5:32.

8. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study on the pitfalls in the evolution of evidence. Arch Intern Med. 2006;166: 161-6.

9. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the Randomized Acetylcysteine for Contrast-In-duced Nephropathy Trial (ACT). Circulation. 2011; 124(11):1250-9.

10. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High dose N-acetylcisteine for the prevention of contrast induced nephropathy. Am J Med. 2009; 122(9):874.e9-15.

11. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180-4.

12. Díaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002; 89(3):356-8.

13. Calabro P, Bianchi R, Crisci M, Caprile M, Bigazzi MC, Palmieri R, et al. Use and efficacy of saline hydratation and N- acetyl cysteine to prevent contrast-induced nephropathy in low-risk popula-tions undergoing coronary artery angiography. Intern Emerg Med. 2011;6(6):503-7.

14. Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu MA, Ayhan S, et al. Intravenous N-acetylcysteine plus high-dose hydratation versus high-dose hy-dration and standard hydration for the prevention of contrast-induced nephropathy: CASIS- a multicenter prospective controlled trial. Int J Cardiol. 2012; 155(3):418-23.

15. Marenzi G, Assanelli E, Marana I, Lauri G, Campo-donico J, Grazi M, et al. N-acetylcysteine and con-trast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354(26):2773-82.

16. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40(2):298-303.

17. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148(3):422-9.